Development of a Targeted Polymorph Screening Approach for a Complex Polymorphic and Highly Solvating API

被引:103
作者
Campeta, Anthony M. [1 ]
Chekal, Brian P. [1 ]
Abramov, Yuriy A. [1 ]
Meenan, Paul A. [1 ]
Henson, Mark J. [1 ]
Shi, Bing [1 ]
Singer, Robert A. [1 ]
Horspool, Keith R. [1 ]
机构
[1] Pfizer Global Res & Dev, Pharmaceut Sci, Groton, CT 06340 USA
关键词
axitinib; polymorphism; polymorph screen; crystallization; desolvation; computational chemistry; crystal structure; APPROXIMATION; CRYSTALLIZATION; BEHAVIOR; ENERGY; FORMS;
D O I
10.1002/jps.22230
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Elucidation of the most stable form of an active pharmaceutical ingredient (API) is a critical step in the development process. Polymorph screening for an API with a complex polymorphic profile can present a significant challenge. The presented case illustrates an extensively polymorphic compound with an additional propensity for forming stable solvates. In all, 5 anhydrous forms and 66 solvated forms have been discovered. After early polymorph screening using common techniques yielded mostly solvates and failed to uncover several key anhydrous forms, it became necessary to devise new approaches based on an advanced understanding of crystal structure and conformational relationships between forms. With the aid of this analysis, two screening approaches were devised which targeted high-temperature desolvation as a means to increase conformational populations and enhance overall probability of anhydrous form production. Application of these targeted approaches, comprising over 100 experiments, produced only the known anhydrous forms, without appearance of any new forms. The development of these screens was a critical and alternative approach to circumvent solvation issues associated with more conventional screening methods. The results provided confidence that the current development form was the most stable polymorph, with a low likelihood for the existence of a more-stable anhydrous form. (C) 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:3874-3886, 2010
引用
收藏
页码:3874 / 3886
页数:13
相关论文
共 31 条
[1]  
ABRAMOV YA, IN PRESS
[2]  
ABRAMOV YA, 2009, COSMO RS S 2009 LEV
[3]  
*ACC, DMOL MAT STUD VERS 4
[4]   INCORPORATION OF SOLVENT EFFECTS INTO DENSITY-FUNCTIONAL CALCULATIONS OF MOLECULAR-ENERGIES AND GEOMETRIES [J].
ANDZELM, J ;
KOLMEL, C ;
KLAMT, A .
JOURNAL OF CHEMICAL PHYSICS, 1995, 103 (21) :9312-9320
[5]  
[Anonymous], 1897, Z. f.ur. Physikalische Chem. Bd, DOI DOI 10.1515/ZPCH-1897-2233
[6]   Ritonavir: An extraordinary example of conformational polymorphism [J].
Bauer, J ;
Spanton, S ;
Henry, R ;
Quick, J ;
Dziki, W ;
Porter, W ;
Morris, J .
PHARMACEUTICAL RESEARCH, 2001, 18 (06) :859-866
[7]   DENSITY-FUNCTIONAL EXCHANGE-ENERGY APPROXIMATION WITH CORRECT ASYMPTOTIC-BEHAVIOR [J].
BECKE, AD .
PHYSICAL REVIEW A, 1988, 38 (06) :3098-3100
[8]  
Bernstein J., 2020, Polymorphism in molecular crystals 2e, Vvol. 30
[9]  
Brittain H.G., 2009, Polymorphism in Pharmaceutical Solids
[10]  
BURGER A, 1979, MIKROCHIM ACTA, V2, P273